Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2008

01-05-2008 | Therapy in Practice

Management of Breakthrough Pain in Patients with Cancer

Authors: Dr Leeroy William, Rod MacLeod

Published in: Drugs | Issue 7/2008

Login to get access

Abstract

Breakthrough pain (BTP) in patients with cancer lacks a consensus definition and is subsequently inadequately diagnosed and assessed, therefore making it more challenging to manage. Cancer pain is generally moderate to severe in intensity and persistent in nature. Despite the problematic definition of BTP, it is generally described as having similar intensity, but may also be transitory and variable in predictability. Most breakthrough analgesia fails to be effective in the time required for BTP. No useful analgesia is therefore provided but drug adverse effects escalate. Cancer pain management relies on the WHO analgesic ladder. The frequency of BTP and its inadequate management means that it has significant adverse effects on patients, their families and those involved in their care. This article outlines a systematic, clinical and evidence-based approach to managing BTP in patients with cancer that emphasizes a holistic approach and an understanding of multidimensional ‘total pain’. Guidelines for managing BTP are presented and areas of developing research are identified.
Literature
1.
Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994 Mar 3; 330(9): 592–6PubMedCrossRef
2.
Hyun MS, Lee JL, Lee KH, et al. Pain and its treatment in patients with cancer in Korea. Oncology 2003; 64(3): 237–44PubMedCrossRef
3.
Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995 Mar; 13(3): 748–55PubMed
4.
Larue F, Colleau SM, Brasseur L, et al. Multicentre study of cancer pain and its treatment in France. BMJ 1995 Apr 22; 310(6986): 1034–7PubMedCrossRef
5.
Portenoy RK, Kornblith AB, Wong G. Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms. Cancer 1994 Aug 1; 74(3): 907–15PubMedCrossRef
6.
Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982 Nov 1; 50(9): 1913–8PubMedCrossRef
7.
Ger LP, Ho ST, Wang JJ, et al. The prevalence and severity of cancer pain: a study of newly-diagnosed cancer patients in Taiwan. J Pain Symptom Manage 1998 May; 15(5): 285–93PubMedCrossRef
8.
9.
Brescia FJ, Portenoy RK, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992 Jan; 10(1): 149–55PubMed
10.
Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995 Apr; 22 (2 Suppl. 3): 67–72PubMed
11.
Tay WK, Shaw RJ, Goh CR. A survey of symptoms in hospice patients in Singapore. Ann Acad Med Singapore 1994 Mar; 23(2): 191–6PubMed
12.
Yun YH, Heo DS, Lee IG, et al. Multicenter study of pain and its management in patients with advanced cancer in Korea. J Pain Symptom Manage 2003 May; 25(5): 430–7PubMedCrossRef
13.
Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81(1–2): 129–34PubMedCrossRef
14.
Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995 Jul; 10(5): 348–55PubMedCrossRef
15.
Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb 1; 94(3): 832–9PubMedCrossRef
16.
Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002 Feb; 3(1): 38–44PubMedCrossRef
17.
Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003 Jan; 25(1): 9–18PubMedCrossRef
18.
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990 Jun; 41(3): 273–81PubMedCrossRef
19.
Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 1998 Jan–Feb; 15(1): 13–22PubMedCrossRef
20.
21.
Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999 Jun; 17(6): 391–401PubMedCrossRef
22.
Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005 Apr; 9(2): 195–206PubMedCrossRef
23.
Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000 Aug; 20(2): 87–92PubMedCrossRef
24.
Stromgren AS, Groenvold M, Petersen MA, et al. Pain characteristics and treatment outcome for advanced cancer patients during the first week of specialized palliative care. J Pain Symptom Manage 2004 Feb; 27(2): 104–13PubMedCrossRef
25.
Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 2004 Apr; 18(3): 177–83PubMedCrossRef
26.
Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes: I ASP task force on Cancer Pain. International Association for the Study of Pain. Pain 1999 Sep; 82(3): 263–74
27.
Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005; 23(2): 182–90PubMedCrossRef
28.
Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003 Jan; 101(1-2): 55–64PubMedCrossRef
29.
Saunders C. The symptomatic treatment of incurable disease. Prescribers J 1964; 4: 68–73
30.
31.
Zeppetella G, Ribeiro MD. Episodic pain in patients with advanced cancer. Am J Hospice Pall Care 2002; 19(4): 267–76CrossRef
32.
Hagen NA, Stiles C, Nekolaichuck C, et al. The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi Process and patient think-aloud interviews. J Pain Symptom Manage 2008; 35(2): 136–52PubMedCrossRef
33.
Bennett D, Burton A, Fishman S, et al. Consensus panel recommendations for the assessment and management of break-through pain: part 2 management. J Clin Pharm Ther 2005; 30(6): 354–61
34.
35.
36.
Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 2001; (3): CD003222
37.
Portenoy RK. Treatment of temporal variations in chronic can-cer pain. Semin Oncol 1997 Oct; 24 (5 Suppl. 16): S16–7–12
38.
Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991 Oct; 6(7): 411–22PubMedCrossRef
39.
Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1987 Feb 15; 59(4): 850–6PubMedCrossRef
40.
Martinez-Zapata MJ, Roque M, Alonso-Coello P, et al. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006; (3): CD003223
41.
Davis MP, Walsh D, Lagman R, et al. Controversies in pharma-cotherapy of pain management. Lancet Oncol 2005 Sep; 6(9): 696–704PubMedCrossRef
42.
Mercadante S, Casuccio A, Agnello A, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage 1999; 17(5): 351–6PubMedCrossRef
43.
McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; (1): CD005180
44.
45.
Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989 May; 7(5): 590–7PubMed
46.
Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; (2): CD002068
47.
Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002 Jul; 10(5): 399–407PubMedCrossRef
48.
Mercadante S, Villari P, Ferrera P, et al. Pamidronate in incident pain due to bone metastases. J Pain Symptom Manage 2001 Aug; 22(2): 630–1PubMedCrossRef
49.
Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004 Nov; 6(3): 170–4PubMedCrossRef
50.
Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004 Oct; 31 (5 Suppl. 10): 67–72PubMedCrossRef
51.
Wu JS, Monk G, Clark T, et al. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol 2006 Sep; 18(7): 539–44CrossRef
52.
Nilsson S, Strang P, Ginman C, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89: a randomized phase II study. J Pain Symptom Manage 2005 Apr; 29(4): 352–7PubMedCrossRef
53.
Ripamonti C, Fagnoni E, Campa T, et al. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 2007 Mar; 15(3): 339–42PubMedCrossRef
54.
Burton AW, Reddy SK, Shah HN, et al. Percutaneous vertebroplasty: a technique to treat refractory spinal pain in the setting of advanced metastatic cancer. A case series. J Pain Symptom Manage 2005 Jul; 30(1): 87–95CrossRef
55.
Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop Relat Res 2003 Oct; 415 Suppl.: S176–86PubMedCrossRef
56.
57.
Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neural 2003 Nov; 60(11): 1524–34CrossRef
58.
Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005 Dec 5; 118(3): 289–305PubMedCrossRef
59.
Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005 Mar 31; 352(13): 1324–34PubMedCrossRef
60.
Hugel H, Eilershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003 Dec; 26(6): 1073–4PubMedCrossRef
61.
Mercadante S, Lodi F, Sapio M, et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995 Oct; 10(7): 564–8PubMedCrossRef
62.
Jackson K, Ashby M, Martin P, et al. ‘Burst’ ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001 Oct; 22(4): 834–42PubMedCrossRef
63.
Good P, Tullio F, Jackson K, et al. Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory (‘triple-agent’) therapy for episodes of acute on chronic pain. Intern Med J 2005 Jan; 35(1): 39–44PubMedCrossRef
64.
Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs 2001 Mar; 2(3): 399–414PubMed
65.
Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994 Jan; 9(1): 12–8PubMedCrossRef
66.
Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007 Feb; 33(2): 217–23PubMedCrossRef
67.
Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain: the Epidural Clonidine Study Group. Pain 1995 Jun; 61(3): 391–9PubMedCrossRef
68.
Rauck RL, Cherry D, Boyer MF, et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003 Oct; 4(8): 441–7PubMedCrossRef
69.
Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978 Jan; 3(1): 40–51PubMedCrossRef
70.
Bruckman JE, Bloomer WD. Management of spinal cord compression. Semin Oncol 1978 Jun; 5(2): 135–40PubMed
71.
Hanks G, Cherny N, Fallon M. Opioid analgesic therapy. In: Doyle D, Hanks G, Cherny N, et al., editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press, 2004: 316–41
72.
Mercadante S, Arcuri E. Breakthrough pain in cancer patients. Pain Clinical Updates 2006; 14(1): 1–4
73.
Twycross RG, Wilcock A, Charlesworth S, et al. Palliative care formulary. 2nd ed. Oxford: Radcliffe Medical Press, 2002
74.
Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006 Jun; 32(4): 304–15PubMedCrossRef
75.
Fishman SM, Wilsey B, Mahajan G, et al. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002 Dec; 3(4): 339–48PubMedCrossRef
76.
Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004; (2): CD003971
77.
Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004 Apr; 27(4): 352–9PubMedCrossRef
78.
79.
Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 Mar 2; 84(5): 587–93PubMedCrossRef
80.
Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002 Aug; 46(7): 759–70PubMedCrossRef
81.
Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 2003 Dec; 106(3): 309–15PubMedCrossRef
82.
Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2004 Dec; 28(6): 619–25PubMedCrossRef
83.
Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000 Jan; 14(1): 57–8PubMedCrossRef
84.
Striebel HW, Pommerening J, Rieger A. Intranasal fentanyl titration for postoperative pain management in an unselected population. Anaesthesia 1993 Sep; 48(9): 753–7PubMedCrossRef
85.
Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006 Jan; 9(1): 1–39PubMed
86.
Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998 Apr 15; 90(8): 611–6PubMedCrossRef
87.
Christie JM, Simmonds M, Patt R, et al. Dose-titration, multi-center study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998 Oct; 16(10): 3238–45PubMed
88.
Fine PG, Marcus M, De Boer AJ, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991 May; 45(2): 149–53PubMedCrossRef
89.
Schwagmeier R, Boerger N, Meissner W, et al. Pharmacokinetics of intranasal alfentanil. J Clin Anesth 1995 Mar; 7(2): 109–13PubMedCrossRef
90.
Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001 Jul; 15(4): 323–8PubMedCrossRef
91.
Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000 Oct; 20(4): 253–8PubMedCrossRef
92.
Duncan A. The use of fentanyl and alfentanil sprays for episodic pain [letter]. Palliat Med 2002 Nov; 16(6): 550PubMedCrossRef
93.
Helmers JH, Noorduin H, Van Peer A, et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989 Sep; 36(5): 494–7PubMedCrossRef
94.
Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75(2): 223–9PubMedCrossRef
95.
Jackson K, Ashby M, Keech J. Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. J Pain Symptom Manage 2002 Jun; 23(6): 450–2PubMedCrossRef
96.
Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91(1–2): 123–30PubMedCrossRef
97.
Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006; (1): CD004311
98.
Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006; 66(18): 2387–93; discussion 94-5PubMedCrossRef
99.
Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 Feb; 59(2): 249–53PubMedCrossRef
100.
Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005; 44(12): 1279–86PubMedCrossRef
101.
Darwish M, Kirby M, Robertson P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006; 45(8): 843–50PubMedCrossRef
102.
Darwish M, Kirby M, Robertson P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther 2006 May; 28(5): 707–14PubMedCrossRef
103.
Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov–Dec;22(9):805–11PubMedCrossRef
104.
Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage 2007 Apr; 33(4): 365–71PubMedCrossRef
105.
Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med 2007; 10(2): 331–7PubMedCrossRef
106.
Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004 Mar; 108(1–2): 17–27PubMedCrossRef
107.
Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20(4): 246–52PubMedCrossRef
108.
Woodruff R. Palliative medicine. 4th ed. Oxford: Oxford University Press, 2004
109.
Walsh D. Pharmacological management of cancer pain. Semin Oncol 2000 Feb; 27(1): 45–63PubMed
110.
Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001 Sep; 93(3): 247–57PubMedCrossRef
111.
Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003 Aug; 74(2): 102–12PubMedCrossRef
112.
Walsh D, Rivera NI, Davis MP. Strategies for pain management: Cleveland Clinic Foundation Guidelines for opioid dosing for cancer pain. Support Cancer Ther 2004; 1: 157–64PubMedCrossRef
113.
Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001 May 1; 19(9): 2542–54PubMed
114.
Mercadante S, Villari P, Ferrera P, et al. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004 Nov; 12(11): 762–6PubMedCrossRef
115.
Morita T, Tei Y, Inoue S. Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med 2003 Aug; 6(4): 557–63PubMedCrossRef
116.
Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003 Dec 1; 89(11): 2027–30PubMedCrossRef
117.
Kloke M. Gaps and junctions between clinical experience and theoretical framework in the use of opioids. Support Care Cancer 2004 Nov; 12(11): 749–51PubMedCrossRef
118.
Enting RH, Mucchiano C, Oldenmenger WH, et al. The ‘pain pen’ for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage 2005 Feb; 29(2): 213–7PubMedCrossRef
119.
Parlow JL, Milne B, Tod DA, et al. Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series. Palliat Med 2005 Jan; 19(1): 3–8PubMedCrossRef
120.
Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain compared to immediate release morphine sulfate tablet. Pain Pract 2007; 7(4): 324–31PubMedCrossRef
121.
Portenoy RK, Messina J, Xie F, et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007 Jan; 23(1): 223–33PubMedCrossRef
Metadata
Title
Management of Breakthrough Pain in Patients with Cancer
Authors
Dr Leeroy William
Rod MacLeod
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868070-00003

Other articles of this Issue 7/2008

Drugs 7/2008 Go to the issue

Leading Article

Novel Thrombopoietic Agents

Review Article

Renal Disease in Patients with HIV Infection

Review Article

Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal Cancer

Correspondence

Drugs in the Newspapers

Adis Drug Evaluation

Posaconazole

Current Opinion

Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor